Clinuvel Pharmaceuticals (CUV) investor relations material

Opening remarks and agenda

• Meeting opened in Melbourne at 10:00 a.m.; quorum confirmed and the Wurundjeri people of the Kulin nation acknowledged as Traditional Owners.

• Agenda covered FY2026 reports, remuneration, director re-elections, a conditional spill resolution, capital markets, allocation, strategy and future plans.

• Formal business and polling were followed by the Managing Director’s update and shareholder questions.

Financial performance review

• Marked 10 consecutive profitable years and a decade without dilution; the first-half result was described as the strongest in history.

• Cash was AUD 252m at June 30, 2026, with no debt; the Chair described cash holdings as more than AUD 260m.

• FY2017–FY2026 cumulative expenses were A$304.8M and net cash reserves increased A$238.3M; 20-year capital required was AUD 356m.

• 2027–2030 capital requirement was estimated at A$220M, excluding CAPEX, communications, branding and marketing; forecast maximum spend was AUD 55m annually for four years, with a three-year OPEX and CAPEX buffer target.

• Share price was described as at a 10-year low; management cited competition fears and biotech valuations but declined to attribute the movement to a single cause.

Board and executive committee updates

• Managing Director Philippe Wolgen extended his agreement to June 30, 2029, without retention awards or long-term incentives; incentives will be revisited against market practice.

• The Chair said Managing Director remuneration was below the median of a selected 40-company U.S. and Australian peer group.

• The Chair urged support for re-electing Dr. Pearl Grimes and Guy van Dievoet; Grimes cited her dermatology expertise and active role in the vitiligo program.

• U.S.-based directors with North American business and investment expertise may be considered if a Nasdaq listing proceeds.